Gabriele Greve

Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation

Nadja Blagitko‐Dorfs, Pascal Schlosser, Gabriele Greve et al. · Leukemia · 2018 · 108 citations

Hematological Malignancy, Hdac Inhibitors, Mixed-phenotype Acute Leukemia +11

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

Gabriele Greve, Insa Schiffmann, Dietmar Pfeifer et al. · BMC Cancer · 2015 · 71 citations · Full text

LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML

Jessica Barth, Khalil Abou‐El‐Ardat, Denis Dalic et al. · Leukemia · 2019 · 67 citations

Tranylcypromine Derivatives, Signal Transduction, Signaling Pathway +8

Structure-activity studies on N -Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation

Johannes Schulz‐Fincke, Mirjam Hau, Jessica Barth et al. · European Journal of Medicinal Chemistry · 2017 · 36 citations · Full text

Tranylcypromine Derivatives, Drug Target, Medicine +11

Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat

Nadja Blagitko‐Dorfs, Yi Jiang, Jesús Duque‐Afonso et al. · PLoS ONE · 2013 · 28 citations · Full text

Mixed-phenotype Acute Leukemia, Genetics, Epigenetic Change +20